This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
What Falling Estimates & Price Mean for INC Research (INCR)
by Zacks Equity Research
INC Research (INCR) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.
Why Earnings Season Could Be Great for INC Research Holdings (INCR)
by Zacks Equity Research
INC Research Holdings (INCR) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Can DENTSPLY (XRAY) Deliver a Beat This Earnings Season?
by Zacks Equity Research
In the third quarter, DENTSPLY (XRAY) is expected to witness strong growth in revenues, particularly in the dental consumables and laboratories segment.
Key Factors to Influence PerkinElmer's (PKI) Q3 Earnings
by Zacks Equity Research
PerkinElmer's (PKI) divestiture of the Medical Imaging segment in the last quarter is expected to impact earnings this season.
AmerisourceBergen (ABC) Q4 Earnings: Will it Disappoint?
by Zacks Equity Research
The temporary slowdown in the PharMEDium segment is expected to mar AmerisourceBergen's (ABC) bottom line in the fourth quarter
Is Becton, Dickinson (BDX) Poised for a Beat in Q4 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) large base of product pipeline, industry-leading technologies and collaborations are growth propellers in Q4.
Ecolab (ECL) to Report Q3 Earnings: Will It Disappoint?
by Zacks Equity Research
Ecolab's (ECL) large base of recurring revenues, industry-leading technologies and excellent field service are propellers. However, the company faces cut-throat competition in the niche space.
What's in Store for Cardinal Health (CAH) in Q1 Earnings?
by Zacks Equity Research
Cardinal Health (CAH), a global player in the healthcare services and products space, has been grappling with pricing deflation in the generics segment in the first quarter.
Will Higher System Sales Drive Cerner's (CERN) Q3 Earnings?
by Zacks Equity Research
Strong growth in licensed software and subscriptions are expected to be the main factors driving systems revenues for Cerner (CERN) in the third quarter of 2017.
Will Sage-Unit Recall Hurt Stryker's (SYK) Q3 Earnings?
by Zacks Equity Research
In August, Stryker (SYK) announced a voluntary recall of the Oral Care line-up, which was offered by the company's Sage-Products unit.
Mckesson (MCK) to Report Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
McKesson Corporation (MCK) expects a strong second quarter owing to a gradually stabilizing generic and branded market.
Medical Services Stock Q1 Earnings on May 10: CRL, XON, INCR
by Zacks Equity Research
Let's see what awaits these three medical services stocks that are slated to release their first-quarter 2017 results on May 10.
Should You Get Rid of INC Research (INCR) Now?
by Zacks Equity Research
INC Research (INCR) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.
Teladoc Announces Stock Sale to Finance Growing Business
by Zacks Equity Research
Teladoc Inc. (TDOC) has announced to sell 5,400,000 shares of its common stock, in an effort to procure funds for expansion.
Teladoc's Client UnitedAg Expands Pact to Get Wider Services
by Zacks Equity Research
Teladoc Inc.'s (TDOC) existing client UnitedAg has expanded its partnership with the former.
VCA Looks to Gain Scale and Size by Being Part of Mars
by Zacks Equity Research
VCA Inc. (WOOF), a provider of pet health care services in the U.S., has agreed to be acquired by Mars, Incorporated.
Teladoc (TDOC) Guidance Reflects Solid Business in '16, '17
by Zacks Equity Research
Teladoc's (TDOC), upbeat guidance for 2016 and 2017 points to strong business growth and superior performance.
Teladoc to Provide Diagnostic Service Via Analyte Health
by Zacks Equity Research
Teladoc (TDOC) has tied up with Analyte Health to provide lab diagnostics services through its telehealth platform.
Teladoc (TDOC) December Business Reveals Outperformance
by Zacks Equity Research
Teladoc Inc. (TDOC) disclosed that in the month of December it crossed more than two million patient visits.
New Strong Buy Stocks for September 15th
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
New Strong Buy Stocks for August 29th
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Top Healthcare Stocks
by Brian Bolan
Paging profits with Medical Services stocks!
Stocks with Upgraded Broker Ratings
by Kevin Matras
Kevin Matras explains why looking for stocks with upgraded broker ratings can upgrade your portfolio to a whole new level. Highlighted stocks include AMCX, AMSG, CINF, INCR and NCI.
Top 5 Medical Service Stocks to Buy
by Brian Hamilton
The Medical sector is one of the top performing sectors for Q3 2015, and it is expected to be a top performer in Q4 2015 too.
Top Medical Services Stocks To Buy
by Brian Bolan
This highly ranked industry is home to a lot of attractive stocks right now.